Lipid nanoparticles for tissue selective delivery of nucleic acid drugs and preparation method and application thereof
Through the design of lipid-like nanoparticles, the combination of ionizable amphiphilic polymers and auxiliary lipids is used to realize the tissue selective delivery of nucleic acid drugs in the body, and solve the problem of the accumulation of nucleic acid drugs in the liver in the prior art. Problem, improving the bioavailability and therapeutic effect of drugs.
Patent Information
- Application Number
- CN202211602837.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-12-13
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2042-12-13
AI Technical Summary
Existing nucleic acid drug delivery systems are difficult to achieve selective delivery of tissues in vivo, especially by intravenous injection, tending to accumulate in the liver and being cleared, resulting in weaker effects, and often using biological targeting molecules or regulatory additive components to achieve them. Tissue selective enrichment and transfection.
Lipid-like nanoparticles composed of ionizable amphiphilic polymers, auxiliary lipids and biostable enhancers are prepared through addition reactions to regulate the inherent characteristics of the polymer to achieve tissue selective delivery of nucleic acid drugs in the body, avoiding the Use biomolecular targeting techniques or altering the external additive components of the material.
The tissue selective delivery of nucleic acid drugs in the body is achieved, reducing liver clearance, improving drug bioavailability, and enriching in specific tissues such as the lungs or liver, inhibiting the development of tumors or liver fibrosis.
Smart Images

Figure BDA0003995947590000081 
Figure HDA0003995947600000011 
Figure HDA0003995947600000012
Abstract
Description
Technical Field
[0001] The invention relates to a lipid nanoparticle for tissue selective delivery of nucleic acid drugs and a preparation method and application thereof, belonging to the field of biomedicine. Background Art
[0002] As a new type of disease treatment, gene therapy is widely used in the treatment of genetic diseases, cancer and vaccine development. The basic principle of gene therapy is to introduce functional normal genes into target cells, correct or compensate for abnormal genes and achieve disease treatment. At present, nucleic acid drugs commonly used in gene therapy mainly include plasmid DNA (pDNA), antisense nucleic acid (ASO), small interfering RNA (siRNA), messenger RNA (mRNA), microRNA (microRNA) and GRISPR-Cas9 gene editing system. Compared with small molecule drugs and antibody drugs, nucleic acid drugs have significant advantages, such as a wide range of effects, regulatory effects on both inside and outside cells, and easy design. However, the development of nucleic acid drugs still faces many obstacles: 1) The molecular weight is relatively large and often carries a negative charge, which makes it impossible to pass through the cell membrane smoothly, resulting in low cell uptake efficiency; 2) Poor stability, easily degraded by enzymes inside and outside the body; 3) It is immunogenic and stimulates immune response after being recognized by the immune system; 4) After entering the body, it is easily cleared by the liver and kidneys; 5) After entering the cell, the efficiency of endosome escape is low. Therefore, developing safe and efficient delivery vectors to compensate for the inherent defects of nucleic acid drugs is crucial to the realization of gene therapy.
[0003] In recent years, nanoparticles formed by various natural or synthetic materials, such as lipids and lipidoids, polymers, peptides, proteins, extracellular vesicles and inorganic nanoparticles, have been designed for in vivo and in vitro delivery of nucleic acid drugs. Among them, nanoparticles (LNPs) based on lipids and lipidoids have been widely used for in vivo and in vitro delivery of nucleic acid drugs due to their good biocompatibility, low immunogenicity and easy batch preparation, and their optimization schemes have been studied in depth. Recently, the LNP-based COVID-19 mRNA vaccine developed by Pfizer and Moderna has been licensed for use, which has once again attracted researchers' attention to LNP as a gene delivery carrier, making it the most popular delivery system at present. In addition, nanoparticles formed by polymers and their derivatives have become an important component of in vivo and in vitro delivery carriers of nucleic acid drugs because they are easy to synthesize. Polymers used for gene delivery should be easily degraded in the body and should not produce toxic components. Among them, linear or branched polyethyleneimine (PEI) is a classic cationic polymer widely used for nucleic acid delivery in vivo and in vitro. It can be used alone or modified to improve transfection efficiency. For example, TarN3C10, DD90-C12-122 and amino polyester (APE) can deliver mRNA into the body and achieve ideal transfection efficiency and safety results after combining with other lipids.
[0004] Nucleic acid drug-based treatments have bright application prospects in addressing genetic diseases, cancer, infectious diseases and other diseases, and certain breakthroughs have been achieved in related technologies. However, there are still major challenges in key issues such as gene delivery, off-target and immunogenicity. In terms of gene delivery, compared with other delivery methods, transfection mediated by various nanoparticle-based formulations shows obvious advantages, such as easy manufacturing, good reproducibility of different batches, good biocompatibility, and the ability to enhance the stability of nucleic acid drugs in the body and thus improve the bioavailability of drugs. In particular, lipid nanoparticles have become one of the most advanced non-viral nucleic acid delivery systems. However, a huge challenge currently facing nucleic acid drug delivery systems is their tissue selectivity. The commonly used nanoparticles that have been developed tend to aggregate in the liver after intravenous injection, and are eventually absorbed by hepatocytes and easily cleared by the liver, resulting in a weakened effect. Although studies have solved the problem of easy clearance by the liver, they all use combined biological targeting molecules or regulatory auxiliary components to achieve tissue-selective delivery of nucleic acid drugs.
[0005] Therefore, it is a current challenge to design and optimize nanodelivery systems to selectively transfer nucleic acid drugs to non-liver tissues after systemic delivery without using biomolecular targeting technology or changing the exogenous auxiliary agent components of the material itself. Summary of the invention
[0006] In order to overcome the limitations of current nucleic acid drug delivery systems, which cannot achieve tissue-selective delivery in vivo, especially the need to use combined biological targeting molecules or regulatory auxiliary components to complete the problem of tissue-selective enrichment and transfection after systemic delivery, the present invention provides lipid nanoparticles for tissue-selective delivery of nucleic acid drugs, and a preparation method and application thereof.
[0007] The present invention is achieved by adopting the following technical solutions:
[0008] A lipid nanoparticle for tissue selective delivery of nucleic acid drugs, wherein the lipid nanoparticle is composed of the following components by mass percentage:
[0009] Ionizable amphiphilic polymer 30-80%, auxiliary lipid 5-60%, biological stability enhancer 5-40%,
[0010] The ionizable amphiphilic polymer is obtained by addition reaction of a polymer rich in amine groups at the head and a lipid containing a hydrophobic hydrocarbon group at the tail chain. The auxiliary lipid is a steroid or a mixture of a steroid and a permanent cationic lipid. The biostabilization enhancer is a pegylated lipid.
[0011] According to the present invention, preferably, the polymer having rich amine groups at the head portion is polyethyleneimine (PEI).
[0012] More preferably, the polyethyleneimine (PEI) is linear PEI (LPEI) or branched PEI (BPEI).
[0013] Most preferably, the polyethyleneimine (PEI) is branched PEI (BPEI).
[0014] Preferably according to the present invention, the molecular weight of polyethyleneimine (PEI) is 0.3 kDa-20 kDa.
[0015] More preferably, the molecular weight of polyethyleneimine (PEI) is 0.3 kDa-10 kDa.
[0016] Preferably according to the present invention, the lipid having a hydrophobic hydrocarbon group in the tail chain is acrylate, acrylamide or epoxide.
[0017] More preferably, the lipid having a hydrophobic hydrocarbon group in the tail chain is an acrylate, and the acrylate is an acrylate having a straight-chain alkyl tail chain, and the number of carbon atoms in the straight-chain alkyl group is C1 to C18.
[0018] Most preferably, the straight chain alkyl group has carbon atoms of C10 to C14.
[0019] Preferably according to the present invention, the ionizable amphiphilic polymer is obtained by an addition reaction between a polymer rich in amine groups at the head and a lipid containing a hydrophobic hydrocarbon group at the tail chain, and the molar ratio of the lipid containing a hydrophobic hydrocarbon group at the tail chain to the polymer rich in amine groups at the head is 0.1-14:1.
[0020] More preferably, the molar ratio of the lipid containing hydrophobic hydrocarbon groups at the tail chain to the polymer rich in amine groups at the head is 6-12:1.
[0021] The higher the molar ratio of lipids containing hydrophobic hydrocarbon groups in the tail chain to polymers rich in amine groups at the head, the higher the modification degree of the ionizable amphiphilic polymer. The lipid nanoparticles obtained from ionizable amphiphilic polymers with different modification degrees have different functions and effects.
[0022] Preferably according to the present invention, the addition reaction is carried out at 80° C.-100° C. and the reaction time is 24-72 hours.
[0023] More preferably, the addition reaction is carried out at 85°C-95°C and for 48-72 hours.
[0024] According to the present invention, preferably, the steroid is selected from cholesterol, β-sitosterol, saposterol, stigmasterol, ergosterol or stigmasterol.
[0025] According to the present invention, the permanent cationic lipid is preferably selected from (2,3-dioleoyl-propyl)-trimethylammonium chloride (DOTAP), dioctadecyldimethylammonium bromide (DDAB) or 1,2-dioctadecenyloxy-3-methylammonium propane (chloride) (DOTMA).
[0026] Preferably according to the present invention, when the helper lipid is a single steroid, the mass percentage of the steroid is 5-20%.
[0027] Preferably according to the present invention, when the auxiliary lipid is a mixture of a steroid and a permanent cationic lipid, the mass percentage of the steroid is 5-20%, and the mass percentage of the permanent cationic lipid is 5-40%.
[0028] Preferably according to the present invention, the amount of steroid alone is the same as the amount of steroid in the mixture of steroid and permanent cationic lipid.
[0029] Preferably according to the present invention, the PEGylated lipid is selected from distearoylphosphatidylethanolamine-polyethylene glycol 2000 (DSPE-PEG), 1,2-dimyristoyl-rac-glycerol-3-methoxy-polyethylene glycol 2000 (DMG-PEG), d-α-tocopheryl succinate polyethylene glycol ester (TPGS), 2-myristyl stannoyl-3-phosphatidylethanolamine-polyethylene glycol 2000 (DMPE-PEG), L-phosphatidylethanolamine-polyethylene glycol 2000 (DPPE-PEG), 1,2-dipalmitoyl-sn-glycerol-polyethylene glycol 2000 (DPG-PEG), and 1,2-distearoyl-sn-glycerol-polyethylene glycol 2000 (DSG-PEG).
[0030] The various PEGylated lipids selected in the present invention are all prior art, see the literature: Surface De-PEGylation Controls Nanoparticle-Mediated siRNA Delivery In Vitro and InVivo, Xi Zhu et al.
[0031] Preferably according to the present invention, the PEGylated lipid is distearoylphosphatidylethanolamine-polyethylene glycol 2000 (DSPE-PEG) or 1,2-dimyristoyl-rac-glycerol-3-methoxy-polyethylene glycol 2000 (DMG-PEG).
[0032] Preferably, according to the present invention, the lipid nanoparticles are composed of the following components by mass percentage:
[0033] The ionizable amphiphilic polymer comprises 36-58%, the auxiliary lipid comprises 10-40%, and the biological stability enhancer comprises 18-38%.
[0034] The method for preparing the lipid nanoparticles for tissue selective delivery of nucleic acid drugs comprises the following steps:
[0035] 1) dissolving an ionizable amphiphilic polymer, an auxiliary lipid and a biostabilizing enhancer in an organic solvent to form a lipid premix solution,
[0036] 2) Add the lipid premix solution dropwise into the buffer solution to form lipid nanoparticles.
[0037] Preferably according to the present invention, the organic solvent is anhydrous ethanol.
[0038] Preferably according to the present invention, the buffer is acetic acid-sodium acetate buffer with a pH of 5.2-7.2.
[0039] According to the preferred embodiment of the present invention, the amount of organic solvent used is a dissolving amount.
[0040] Preferably, according to the present invention, the amount of buffer used is such that the resulting mixture is a colloidal dispersion.
[0041] The application of the lipid nanoparticles for tissue selective delivery of nucleic acid drugs is used to deliver therapeutic drugs.
[0042] Preferably according to the present invention, the therapeutic drug is one or a mixture of small molecules, proteins and nucleic acids.
[0043] Preferably according to the present invention, the therapeutic drug is a nucleic acid.
[0044] Preferably according to the present invention, the nucleic acid is selected from antisense oligonucleotides (ASO), small interfering RNA (siRNA), messenger RNA (mRNA), microRNA (microRNA), clustered regularly interspaced short palindromic repeats (GRISPR)-related nucleic acids, single guide RNA (sgRNA) and plasmid DNA (pDNA).
[0045] According to the preferred embodiment of the present invention, the specific application method is as follows:
[0046] The therapeutic drug is mixed with the above-mentioned lipid nanoparticles to form a lipid nanoparticle-nucleic acid drug complex, and the lipid nanoparticle-nucleic acid drug complex is applied to an organism to achieve delivery in the organism, selectively enrich the biological tissue and exert its effect.
[0047] Preferably according to the present invention, the mass ratio of the therapeutic drug to the lipid nanoparticles is 1:(0.5-50).
[0048] Further preferably, the mass ratio of the therapeutic drug to the lipid nanoparticles is 1:(7-15).
[0049] Preferably according to the present invention, the administration method includes intravenous injection, intramuscular injection, nasal inhalation, oral administration, subcutaneous injection, and tracheal administration.
[0050] The lipid nanoparticle-nucleic acid drug complex of the present invention can be selectively enriched in the heart, liver, spleen, lung and kidney biological tissues and exert its effect.
[0051] The technical features and advantages of the present invention are as follows:
[0052] 1. The lipid nanoparticles for tissue-selective delivery of nucleic acid drugs of the present invention are based on ionizable amphiphilic polymers. When used to deliver therapeutic drugs, the tissue-selective delivery of nucleic acid drugs in the subject organism is achieved by adjusting the inherent properties of the polymer itself, without the need to use biomolecular targeting technology or change the exogenous auxiliary component of the material itself.
[0053] 2. The lipid nanoparticles for tissue-selective delivery of nucleic acid drugs of the present invention do not require the use of combined biological targeting molecules or regulatory auxiliary components to achieve tissue-selective delivery of nucleic acid drugs, are not easily cleared by the liver, and can be enriched in the liver to inhibit the development of liver fibrosis.
[0054] 3. The key to achieving tissue-selective delivery of nucleic acid drugs in the subject organism is the molar ratio of the lipid containing hydrophobic hydrocarbon groups in the tail chain to the polymer rich in amine groups in the head. Within a specific molar ratio range, the ionizable amphoteric polymer in the obtained lipid nanoparticles has different selectivities. When the modification degree is high, the nucleic acid drugs are easily carried and enriched in the liver to exert their effects to inhibit the development of liver fibrosis, while when the modification degree is low, the nucleic acid drugs are more likely to be delivered to the lungs and exert their effects to inhibit the lung metastasis of tumors.
[0055] 4. The molar ratio of the lipid containing a hydrophobic hydrocarbon group in the tail chain to the polymer rich in amine groups in the head of the present invention is 6-10:1, and the modification degree of the ionizable amphiphilic polymer is low. The lipid nanoparticles obtained from the low-modification ionizable amphiphilic polymer have strong lung selectivity and are highly selectively enriched in the lungs to inhibit the lung metastasis of tumors.
[0056] 5. The present invention can stimulate further breakthroughs in the field of nucleic acid drug delivery and promote the development of various innovative treatment modes such as gene therapy. BRIEF DESCRIPTION OF THE DRAWINGS
[0057] Figure 1 These are the H-NMR spectra of ionizable amphiphilic polymers with different degrees of hydrophobic carbon chain modification.
[0058] Figure 2A , 2B , 2C is the preparation flow chart, appearance diagram, and characterization diagram of lipid nanoparticles. Figure 2A Schematic diagram of the preparation process of lipid nanoparticles; Figure 2B This is the appearance of lipid nanoparticles. Figure 2C Characterization of the physicochemical properties of lipid nanoparticles, a is the hydrated particle size, b is the zeta potential, c is the polydispersity coefficient, and d is the morphology.
[0059] Figure 3A and 3B These are diagrams showing the transfection effects of lipid nanoparticle-nucleic acid complexes on Hela cells in vitro in Experimental Examples 1 and 2. Figure 3A The transfection efficiency of lipid nanoparticle-enhanced green fluorescent protein mRNA (mEGFP) complexes in Hela cells in vitro, including fluorescence microscopy imaging and flow cytometry quantitative analysis; Figure 3BThe gene knockout efficiency of lipid nanoparticle-siRNA targeting enhanced green fluorescent protein mRNA (siEGFP) complex in Hela-EGFP cells in vitro, including fluorescence microscopy imaging and flow cytometry quantitative analysis.
[0060] Figures 4A-4D This is a diagram showing the selective enrichment and transfection effect of lipid nanoparticle-mRNA complexes in various tissues in vivo after intravenous injection in Experimental Example 3, wherein the lipid nanoparticles are labeled with DiR or DiO fluorescent dyes. Figure 4A The in vitro fluorescence imaging images and quantitative analysis of the main organs (heart, liver, spleen, lung, and kidney) of mice 6 hours after intravenous injection of DiR-labeled lipid nanoparticle-mRNA complexes; Figure 4B The in vitro bioluminescence imaging images and quantitative analysis of the main organs (heart, liver, spleen, lung, and kidney) of mice 6 hours after intravenous injection of lipid nanoparticle-luciferase mRNA (mLuc) complex; Figure 4C Six hours after intravenous injection of DiO-labeled lipid nanoparticle-mRNA complexes, three types of cells (endothelial cells, epidermal cells, and immune cells) in lung tissue were labeled with fluorescently labeled antibodies, and the fluorescence quantitative analysis of the three types of cells was performed using flow cytometry; Figure 4D In vitro fluorescence imaging images and quantitative analysis of the main organs (heart, liver, spleen, lung, and kidney) of mice 6 hours after intravenous injection of DiR-labeled lipid nanoparticles-(mLuc+siTie2) and DiR-labeled lipid nanoparticles-(mLuc+siItgb1) complexes, as well as quantitative analysis of gene knockout in the lung. Among them, siTie2 and siItgb1 are siRNAs for specific genes in lung endothelial cells and lung epithelial cells, respectively.
[0061] Figures 5A-5C This is a diagram showing the selective enrichment and gene knockout effect of lipid nanoparticle-siRNA complexes in various tissues in vivo after intravenous injection in Experimental Example 3, wherein the lipid nanoparticles are labeled with DiR or DiO fluorescent dyes. Figure 5A The in vitro fluorescence imaging images and quantitative analysis of the main organs (heart, liver, spleen, lung, and kidney) of mice 4 hours after intravenous injection of DiR-labeled lipid nanoparticle-siRNA complexes; Figure 5B The invention is a quantitative analysis of gene knockout in the liver and lung of mice 48 hours after intravenous injection of lipid nanoparticle-siRNA complex, wherein the siRNA is a specific siRNA, including siRNA of specific genes in lung endothelial cells (siTie2, siCD31), siRNA of specific genes in lung epithelial cells (siItgb1), and siRNA of specific genes in hepatocytes (siF7); Figure 5CFour hours after intravenous injection of DiO-labeled lipid nanoparticle-siRNA complexes, three types of cells (endothelial cells, epidermal cells, and immune cells) in lung tissue were labeled with fluorescently labeled antibodies, and the fluorescence quantitative analysis of the three types of cells was performed using flow cytometry;
[0062] Figure 6A-6B This figure shows the therapeutic effect of lipid nanoparticle-functional siRNA complex on the lung metastasis model of tumor and liver fibrosis model. Fig. 6A To detect the inhibitory effect of lung metastasis in a tumor lung metastasis model induced by intravenous injection of melanoma cells (B16F10) after continuous intravenous injection of lung-selective lipid nanoparticle-siCD31 complexes for a period of time, including lung images and quantification of melanoma on its surface and the weight change curve of mice; Figure 6B To examine the inhibitory effect of liver fibrosis on a CCl4-induced liver fibrosis model after continuous intravenous injection of liver-selective lipid nanoparticle-siCol1α1 complexes for a period of time, including quantitative analysis of the knockout efficiency of the target gene and immunohistochemical analysis of collagen fibers and α-smooth muscle actin (α-SMA) in liver tissue.
[0063] Figure 7A-7B The biocompatibility of lipid nanoparticle-nucleic acid complexes in vivo and in vitro. Fig. 7A The effect of lipid nanoparticle-nucleic acid complexes at different concentrations on the activity of Hela cells in vitro; Figure 7B To investigate the pathological effects of lipid nanoparticle-nucleic acid complexes on various tissues in vivo at concentrations that achieve effective transfection. DETAILED DESCRIPTION
[0064] The following content further describes the present invention in combination with specific embodiments, but the present invention is not limited to the following embodiments.
[0065] Example 1
[0066] The preparation method of the ionizable amphiphilic polymer comprises the following steps:
[0067] The branched PEI with a molecular weight of 0.6 kDa was mixed with an acrylic acid ester containing a 12-carbon straight alkyl tail chain at a molar ratio of 1:6, 1:8, 1:9, 1:10, 1:11, and 1:12, respectively, and heated and stirred at 90 °C in the dark for 48 hours. The obtained crude product was dialyzed in anhydrous ethanol and dried to remove the ethanol, and polymers with different hydrophobic chain modification degrees were obtained and named nC 12, where n represents the molar ratio of acrylate to PEI. The obtained polymer was analyzed by H-NMR spectrum and the modification degree of the alkyl chain was calculated. The modification degree of the polymer obtained by different molar ratios of acrylate to PEI is shown in Table 1 below:
[0068] Table 1
[0069]
[0070] The H NMR spectra of different ionizable amphiphilic polymers are shown in Figure 2. Figure 1 shown.
[0071] Example 2
[0072] A method for preparing lipid nanoparticles for tissue selective delivery of nucleic acid drugs, the preparation process is as follows Figure 2A As shown, the steps are as follows:
[0073] The different ionizable amphiphilic polymers nC prepared in Example 1 were 12 , auxiliary lipid cholesterol and biostabilization enhancer DSPE-PEG2000 were mixed in a mass ratio of 58%, 14% and 28%, respectively, and then dissolved in anhydrous ethanol to obtain a lipid premix, which was added dropwise to an acetic acid-sodium acetate buffer solution with a pH of 5.4 to form a colloidal dispersion (such as Figure 2B As shown), 6 different lipid nanoparticles were obtained and named nC 12 -NP.
[0074] Characterization of lipid nanoparticles Figure 2C As shown, the obtained composite is a spherical structure, and its hydrated particle size is in the range of 100nm-230nm and is relatively uniform. In addition, its zeta potential is positive.
[0075] Example 3
[0076] The 6 different lipid nanoparticles prepared in Example 2 were 12 -NP was mixed with mRNA at a mass ratio of 15:1 to form lipid nanoparticle-nucleic acid drug complexes, and 6 complexes for selective delivery of nucleic acid drugs to different tissues were obtained.
[0077] Example 4
[0078] The 6 different lipid nanoparticles prepared in Example 2 were 12 -NP was mixed with siRNA at a mass ratio of 7.5:1 to form lipid nanoparticle-nucleic acid drug complexes, and 6 complexes for selective delivery of nucleic acid drugs to different tissues were obtained.
[0079] Experimental Example 1
[0080] The six different complexes obtained in Example 3 were co-incubated with Hela cells at a dosage of 0.4 μg / ml of mRNA, wherein the mRNA was determined to be mEGFP, and co-incubated in a carbon dioxide incubator at 37°C for 24 hours, and a blank control was made. The expression of EGFP in Hela cells was observed by fluorescence microscopy and quantitatively analyzed by flow cytometry. The results are as follows: Figure 3A As shown in Figure 2, the transfection efficiency of the complex on Hela cells increases with the increase of the alkyl chain modification degree, especially 10C 12 -NP, 11C 12 -NP, 12C 12 The three complexes corresponding to α-NP showed excellent transfection efficiency.
[0081] Experimental Example 2
[0082] The six different complexes obtained in Example 4 were co-incubated with Hela-EGFP cells at a dosage of 50 nM of siRNA, wherein the siRNA was determined to be siEGFP, and co-incubated in a carbon dioxide incubator at 37°C for 48 hours, and a blank control was made. The knockout of EGFP in Hela-EGFP cells was observed using a fluorescence microscope and quantitatively analyzed by flow cytometry. The results are shown in FIG. Figure 3B As shown in Figure 2, the knockout efficiency of the complex on EGFP in Hela-EGFP cells increased with the increase of alkyl chain modification, especially 10C 12 -NP, 11C 12 -NP, 12C 12 The three complexes corresponding to -NP showed excellent gene knockdown efficiency.
[0083] Experimental Example 3
[0084] According to the results of Experimental Example 1, the 10C obtained in Example 2 was selected. 12 -NP and 12C 12 The complex corresponding to -NP was injected into mice via intravenous injection at a dosage of 0.2 μg / g of mRNA. The selective enrichment and transfection of the complex in various tissues of the mice were observed 6 hours after the injection. Figure 4A The lipid nanoparticles shown in the figure have been labeled with DiR, and the tissue-selective enrichment of the complexes in mice was observed by ex vivo fluorescence imaging of major organs. Notably, in the liver, 12C 12 The enrichment of -NP / mRNA complexes was significantly higher than that of 10C 12 -NP / mRNA complex, while in the lungs, 10C 12 The enrichment of -NP / mRNA complex was significantly higher than that of 12C 12 -NP / mRNA complex. Figure 4BThe mRNA contained in the complex shown in the figure is determined as mLuc, and the transfection efficiency of the complex in various tissues in the mouse body is evaluated by in vitro bioluminescence imaging of the luciferin signal of major organs. 12 -NP / mLuc transfection efficiency in liver is significantly higher than that of 10C 12 -NP / mLuc, while 10C 12 -NP / mLuc transfection efficiency in lungs is significantly higher than that of 12C 12 On this basis, three types of cells in lung tissue (endothelial cells, epidermal cells, and immune cells) were labeled with fluorescently labeled antibodies, and the three types of cells were quantitatively analyzed by flow cytometry to determine the expression of 10C 12 -The main cell types transfected by NP / mLuc in the lung, where the lipid nanoparticles have been labeled with DiO. Figure 4C It shows that 10C 12 -NP / mLuc accumulates in the lungs and mainly transfects lung endothelial cells. 12 After intravenous injection of siRNA and mRNA loaded on NP, the specific gene knockdown of 10C in lung endothelial cells was verified by detecting siRNA. 12 -NP / mRNA specific transfection of lung endothelial cells ( Figure 4D ), while lung epithelial cells were barely transfected.
[0085] Experimental Example 4
[0086] According to the results of Experimental Example 2, the 10C 12 -NP and 12C 12 The complex corresponding to -NP was injected into mice by intravenous injection at a dosage of 0.6 μg / g siRNA, and the selective enrichment effect of the complex in various tissues of mice was observed 4 hours after the injection. Figure 5A As shown, lipid nanoparticles were labeled with DiR, and tissue-selective enrichment of the complexes in mice was observed by ex vivo fluorescence imaging of major organs. 12 The enrichment of NP / siRNA complex was significantly higher than that of 10C 12 -NP / siRNA complexes, while in the lungs, 10C 12 The enrichment of -NP / siRNA complex was significantly higher than that of 12C 12-NP / siRNA complex. The siRNA corresponding to the hepatocyte-specific gene F7, the endothelial cell-specific genes Tie2 and CD31, and the epidermal cell-specific gene Itgb1 were selected to form a complex with lipid nanoparticles, and the gene knockout efficiency of each complex was evaluated by detecting the mRNA level of each gene in the liver and lung 48 hours after intravenous injection. Figure 5B As shown, 12C 12 -NP / siRNA gene knockdown efficiency in hepatocytes was significantly higher than that of 10C 12 -NP / siRNA, while 10C 12 -NP / siRNA has a significantly higher gene knockdown efficiency in lung endothelial cells than 12C 12 -NP / siRNA. In addition, 10C 12 -NP / siRNA had extremely low gene knockdown efficiency in lung epithelial cells. Figure 5C Further evidence of 10C 12 -NP / siRNA mainly accumulates in lung endothelial cells.
[0087] Experimental Example 5
[0088] According to the results of Experimental Example 4, 10C was selectively enriched and transfected in the lung. 12 -NP / siRNA and liver selectively enriched and transfected 12C 12 -NP / siRNA delivered functional siRNA (siCD31 and siCol1α1) to treat the lung metastasis model and liver fibrosis model of tumors, respectively.
[0089] Select 10C obtained in Example 2 12 -NP / siRNA complex, wherein the siRNA is determined to be siCD31 and its dosage is 1.0 mg / kg. Fig. 6A Schematic diagram of the experimental process in which a lung metastasis model of tumor was established by intravenous injection of melanoma cells (B16F10) and multiple 10C 12 -NP / siCD31 was injected intravenously. The whole lungs were harvested 72 hours after the last injection of the complex, and the growth of melanoma on the lung surface was observed and quantified. The results showed that 10C 12 -NP loaded with siCD31 can effectively inhibit the lung metastasis of tumors. 12 -NP / siRNA complex and its mass ratio was determined to be 15:1, wherein siRNA was determined to be siCol1α1 and its dosage was 0.8 mg / kg. Figure 6B Schematic diagram of the experimental process in which a liver fibrosis model was established by regular intraperitoneal injection of CCl4 and multiple intravenous injections of 12C12 -NP / siCol1α1 was used for treatment. After the treatment cycle, the liver was harvested, the mRNA level of Col1α1 in the liver tissue was quantified, and the fibrosis indicators (collagen fibers and α-smooth muscle actin (α-SMA)) were analyzed by immunohistochemistry. The results showed that the liver-selective 12C 12 -NP loaded with siCol1α1 can effectively inhibit the development of liver fibrosis.
[0090] Experimental Example 6
[0091] The six different complexes obtained in Example 2 were incubated with Hela cells at mRNA concentrations of 0.2, 0.4, and 0.6 μg / ml, respectively, and blank controls were used. After incubation in a carbon dioxide incubator at 37°C for 24 hours, the survival rate of Hela cells was detected by MTT assay. The results are shown in Table 2. Fig. 7A As shown, it is shown that the complex has no significant effect on the growth activity of Hela cells at three different mRNA dosages, indicating that the lipid nanoparticles of the present invention have good biocompatibility in vivo and in vitro.
[0092] According to the results of Experimental Example 3, the 10C 12 -NP and 12C 12 The complex corresponding to -NP was injected into mice by intravenous injection at a dosage of 0.2μg / g mRNA, and a blank control was used. 24 hours after the injection, the heart, liver, spleen, lung, and kidney of the mice were extracted and pathologically examined by hematoxylin / eosin (H&E) staining. The results are shown in Figure 7B As shown, the complex has no obvious toxicity to various tissues in mice at a dose that achieves effective transfection in vivo.
[0093] Example 3
[0094] The method for preparing lipid nanoparticles for tissue selective delivery of nucleic acid drugs is the same as that described in Example 2, except that:
[0095] The different ionizable amphiphilic polymers nC prepared in Example 1 were 12 , auxiliary lipid cholesterol and biological stability enhancer DSPE-PEG2000 are mixed in a mass ratio of 50%, 14% and 36% respectively, and the rest is carried out as in Example 1.
[0096] The ionizable amphiphilic polymer comprises 36-58%, the auxiliary lipid comprises 10-40%, and the biological stability enhancer comprises 18-38%.
[0097] Example 4
[0098] The method for preparing lipid nanoparticles for tissue selective delivery of nucleic acid drugs is the same as that described in Example 2, except that:
[0099] The different ionizable amphiphilic polymers nC prepared in Example 1 were 12 , auxiliary lipid β-sitosterol and biostabilization enhancer 1,2-dimyristoyl-rac-glycerol-3-methoxy-polyethylene glycol 2000 (DMG-PEG) were mixed in a mass ratio of 58%, 14% and 28%, respectively, and the rest was carried out as in Example 1.
[0100] Example 5
[0101] The method for preparing lipid nanoparticles for tissue selective delivery of nucleic acid drugs is the same as that described in Example 2, except that:
[0102] The different ionizable amphiphilic polymers nC prepared in Example 1 were 12 , cholesterol, (2,3-dioleoyl-propyl)-trimethylammonium chloride (DOTAP) and bio-stabilization enhancer DSPE-PEG2000 were mixed in a mass ratio of 50%, 14%, 20% and 16%, respectively, and the rest was carried out as in Example 1.
Claims
1. A lipid nanoparticle for tissue selective delivery of a nucleic acid drug, wherein the lipid nanoparticle is composed of the following components by mass percentage: Ionizable amphiphilic polymer 30-80%, auxiliary lipid 5-60%, bio-stabilization enhancer 5-40%, The ionizable amphiphilic polymer is obtained by an addition reaction between a polymer rich in amine groups at the head and a lipid containing a hydrophobic hydrocarbon group at the tail chain, the auxiliary lipid is a steroid or a mixture of a steroid and a permanent cationic lipid, and the biostabilization enhancer is a pegylated lipid; the polymer rich in amine groups at the head is a branched polyethyleneimine, and the molecular weight of the branched polyethyleneimine is 0.3kDa-20kDa; The steroid is selected from cholesterol, β-sitosterol, saposterol, stigmasterol, ergosterol or stigmasterol, and the permanent cationic lipid is selected from (2,3-dioleoyl-propyl)-trimethylammonium chloride, dioctadecyldimethylammonium bromide or 1,2-dioctadecenyloxy-3-methylammonium propane (chloride salt); The lipid with a hydrophobic hydrocarbon group in the tail chain is an acrylate, and the acrylate is an acrylate with a straight-chain alkyl tail chain, and the carbon number of the straight-chain alkyl group is C10 to C14; The molar ratio of the lipid containing hydrophobic hydrocarbon groups at the tail chain to the polymer rich in amine groups at the head is 6-12:1, the reaction temperature is 80° C.-100° C., and the reaction time is 24-72 hours.
2. The lipid nanoparticle for tissue selective delivery of nucleic acid drugs according to claim 1, characterized in that: When the auxiliary lipid is a single steroid, the mass percentage of the steroid is 5-20%; when the auxiliary lipid is a mixture of steroid and permanent cationic lipid, the mass percentage of the steroid is 5-20%, and the mass percentage of the permanent cationic lipid is 5-40%.
3. The lipid nanoparticle for tissue selective delivery of nucleic acid drugs according to claim 1, characterized in that: The PEGylated lipid is selected from distearoylphosphatidylethanolamine-polyethylene glycol 2000, 1,2-dimyristoyl-rac-glycero-3-methoxy-polyethylene glycol 2000, d-α-tocopheryl succinate polyethylene glycol ester, 2-myristyl stannaoyl-3-phosphatidylethanolamine-polyethylene glycol 2000, L-phosphatidylethanolamine-polyethylene glycol 2000, 1,2-dipalmitoyl-sn-glycerol-polyethylene glycol 2000, and 1,2-distearoyl-sn-glycerol-polyethylene glycol 2000.
4. A method for preparing lipid nanoparticles for tissue selective delivery of nucleic acid drugs according to any one of claims 1 to 3, comprising the following steps: 1) Dissolve the ionizable amphiphilic polymer, auxiliary lipid and bio-stabilizing enhancer in an organic solvent to form a lipid premix. 2) Add the lipid premix dropwise into the buffer to form lipid nanoparticles; The organic solvent is anhydrous ethanol, The buffer is acetic acid-sodium acetate buffer with a pH of 5.2-7.
2. The amount of organic solvent used is the amount of dissolution. The amount of buffer used is such that the resulting mixture is a colloidal dispersion.
5. Use of the lipid nanoparticles for tissue selective delivery of nucleic acid drugs according to claim 1 for preparing delivery of nucleic acid therapeutic drugs; in, The nucleic acid is selected from the group consisting of antisense oligonucleotides, small interfering RNA, messenger RNA, microRNA, single guide RNA, and plasmid DNA.
Citation Information
Patent Citations
MRNA nucleic acid drug intracellular delivery system, preparation method and application
CN111467321A
Compositions and methods for organ specific delivery of nucleic acids
CN112996519A
Nanometer delivery system and preparation method and application thereof
CN114099699A
Lipid nanoparticles for in vivo drug delivery and uses thereof
CN114302715A
Lipid nanoparticle formulation
EP3315125A1
